KR100671632B1 - 치료제로 유용한 티에노피리딘의 벤조융합된 헤테로아릴 아마이드 유도체 - Google Patents
치료제로 유용한 티에노피리딘의 벤조융합된 헤테로아릴 아마이드 유도체 Download PDFInfo
- Publication number
- KR100671632B1 KR100671632B1 KR1020047020286A KR20047020286A KR100671632B1 KR 100671632 B1 KR100671632 B1 KR 100671632B1 KR 1020047020286 A KR1020047020286 A KR 1020047020286A KR 20047020286 A KR20047020286 A KR 20047020286A KR 100671632 B1 KR100671632 B1 KR 100671632B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- prepared
- thieno
- mmol
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(C(N(C[C@]3*)C[C@@]3OC)=O)cc2ncc1 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(C(N(C[C@]3*)C[C@@]3OC)=O)cc2ncc1 0.000 description 6
- KKGOMHQLUWLEQT-CYBMUJFWSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(CC1)C[C@@H]1O)=O)c2 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(CC1)C[C@@H]1O)=O)c2 KKGOMHQLUWLEQT-CYBMUJFWSA-N 0.000 description 2
- OUYIBIZVWMZHBK-INIZCTEOSA-N Cc([s]c1c2)c(C(NC3CC3)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](CO)CCC1)=O)c2 Chemical compound Cc([s]c1c2)c(C(NC3CC3)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](CO)CCC1)=O)c2 OUYIBIZVWMZHBK-INIZCTEOSA-N 0.000 description 2
- FFLJPVNUJBZIAD-UHFFFAOYSA-N CC(C)(c1c[s]c(-c2cc(nccc3Oc4ccc5c(C(NC)=O)c(C)[n](C)c5c4)c3[s]2)n1)O Chemical compound CC(C)(c1c[s]c(-c2cc(nccc3Oc4ccc5c(C(NC)=O)c(C)[n](C)c5c4)c3[s]2)n1)O FFLJPVNUJBZIAD-UHFFFAOYSA-N 0.000 description 1
- CRBVDFOWRRJNFD-SFHVURJKSA-N CC(C)CNC(c1c(C)[o]c2cc(Oc3c4[s]c(C(N5[C@H](COC)CCC5)=O)cc4ncc3)ccc12)=O Chemical compound CC(C)CNC(c1c(C)[o]c2cc(Oc3c4[s]c(C(N5[C@H](COC)CCC5)=O)cc4ncc3)ccc12)=O CRBVDFOWRRJNFD-SFHVURJKSA-N 0.000 description 1
- DBPWQBFRGXKKDS-IUDNXUCKSA-N CC(NC(C1C=C2)C=C2Oc2ccnc3c2[s]c(C(N(CC2)C[C@@H]2O)=O)c3)=C1C(NC)=O Chemical compound CC(NC(C1C=C2)C=C2Oc2ccnc3c2[s]c(C(N(CC2)C[C@@H]2O)=O)c3)=C1C(NC)=O DBPWQBFRGXKKDS-IUDNXUCKSA-N 0.000 description 1
- WIJTYEARAXHDSA-YSSOQSIOSA-N CC(c1cc2nccc(Oc3ccc(c(C(NC)=O)c[n]4C)c4c3)c2[s]1)N(CC1)C[C@@H]1O Chemical compound CC(c1cc2nccc(Oc3ccc(c(C(NC)=O)c[n]4C)c4c3)c2[s]1)N(CC1)C[C@@H]1O WIJTYEARAXHDSA-YSSOQSIOSA-N 0.000 description 1
- MJSMYCJEAQKSRO-UHFFFAOYSA-N CC1C=CN=C2C=C(c3c[n-][n+](C)c3)SC12 Chemical compound CC1C=CN=C2C=C(c3c[n-][n+](C)c3)SC12 MJSMYCJEAQKSRO-UHFFFAOYSA-N 0.000 description 1
- XCNNMTCKXBUXMA-UHFFFAOYSA-N CC1C=CN=C2C=C(c3nc(C=O)ccc3)SC12 Chemical compound CC1C=CN=C2C=C(c3nc(C=O)ccc3)SC12 XCNNMTCKXBUXMA-UHFFFAOYSA-N 0.000 description 1
- WPYZXRYDNCHLNB-UHFFFAOYSA-N CCC(c1cc(nccc2Oc3ccc4c(C(NCCCN5CCOCC5)=O)c(C)[n](C)c4c3)c2[s]1)=O Chemical compound CCC(c1cc(nccc2Oc3ccc4c(C(NCCCN5CCOCC5)=O)c(C)[n](C)c4c3)c2[s]1)=O WPYZXRYDNCHLNB-UHFFFAOYSA-N 0.000 description 1
- WNCMXXDEVZOEOE-RQZCQDPDSA-N CCC/C=N/C(c1c(C)[n](C)c2cc([O]=C)ccc12)=O Chemical compound CCC/C=N/C(c1c(C)[n](C)c2cc([O]=C)ccc12)=O WNCMXXDEVZOEOE-RQZCQDPDSA-N 0.000 description 1
- OFJPRJFJYATTGE-UHFFFAOYSA-N CCCCNC(c1c(C)[n](C)c2cc(O)ccc12)=O Chemical compound CCCCNC(c1c(C)[n](C)c2cc(O)ccc12)=O OFJPRJFJYATTGE-UHFFFAOYSA-N 0.000 description 1
- MJMGTBSHBUNTEJ-YRNVUSSQSA-N CCOC(/C=C(\C(F)(F)F)/Nc1cc(OC)ccc1I)=O Chemical compound CCOC(/C=C(\C(F)(F)F)/Nc1cc(OC)ccc1I)=O MJMGTBSHBUNTEJ-YRNVUSSQSA-N 0.000 description 1
- SKZAPOOLQQGQEM-UHFFFAOYSA-N CC[n]1c2cc(OC)ccc2c(C(C(F)(F)F)=O)c1C Chemical compound CC[n]1c2cc(OC)ccc2c(C(C(F)(F)F)=O)c1C SKZAPOOLQQGQEM-UHFFFAOYSA-N 0.000 description 1
- HGPLZMQMVPEWIE-UHFFFAOYSA-N CCc([o]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(-c3ncc[n]3C)cc2ncc1 Chemical compound CCc([o]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(-c3ncc[n]3C)cc2ncc1 HGPLZMQMVPEWIE-UHFFFAOYSA-N 0.000 description 1
- ARGYNMKYEZDWNC-UHFFFAOYSA-N CCc([s]c1c2)c(C(NC)=O)c1ccc2O Chemical compound CCc([s]c1c2)c(C(NC)=O)c1ccc2O ARGYNMKYEZDWNC-UHFFFAOYSA-N 0.000 description 1
- CBVBKGITBAPGJQ-UHFFFAOYSA-N CNC(c(c(c([n]1C)c2)ccc2OC)c1Cl)=O Chemical compound CNC(c(c(c([n]1C)c2)ccc2OC)c1Cl)=O CBVBKGITBAPGJQ-UHFFFAOYSA-N 0.000 description 1
- ALTIHNKZQMTOFA-UHFFFAOYSA-N CNC(c1c[n](C)c2cc(O)ccc12)=O Chemical compound CNC(c1c[n](C)c2cc(O)ccc12)=O ALTIHNKZQMTOFA-UHFFFAOYSA-N 0.000 description 1
- LVJCPNGUASRZQF-OAHLLOKOSA-N CNC(c1c[n](C)c2cc(Oc3ccnc4c3[s]c(C(N(CC3)C[C@@H]3OC)=O)c4)ccc12)=O Chemical compound CNC(c1c[n](C)c2cc(Oc3ccnc4c3[s]c(C(N(CC3)C[C@@H]3OC)=O)c4)ccc12)=O LVJCPNGUASRZQF-OAHLLOKOSA-N 0.000 description 1
- POZQTSVBFIYXQI-BETUJISGSA-N CO[C@H](CN(C1)C(OCc2ccccc2)=O)[C@H]1OC Chemical compound CO[C@H](CN(C1)C(OCc2ccccc2)=O)[C@H]1OC POZQTSVBFIYXQI-BETUJISGSA-N 0.000 description 1
- GOJMXNVZLAXITF-PHIMTYICSA-N CO[C@H](CN(C1)C(c2cc3nccc(Cl)c3[s]2)=O)[C@H]1OC Chemical compound CO[C@H](CN(C1)C(c2cc3nccc(Cl)c3[s]2)=O)[C@H]1OC GOJMXNVZLAXITF-PHIMTYICSA-N 0.000 description 1
- ZGTPNJQKMOHUOD-UHFFFAOYSA-N COc1cccc(-c2cc3nccc(Cl)c3[s]2)n1 Chemical compound COc1cccc(-c2cc3nccc(Cl)c3[s]2)n1 ZGTPNJQKMOHUOD-UHFFFAOYSA-N 0.000 description 1
- GZRZBGSFUXNRJK-UHFFFAOYSA-N C[n]1c2cc(OC)ccc2c(C(O)=O)c1C(F)(F)F Chemical compound C[n]1c2cc(OC)ccc2c(C(O)=O)c1C(F)(F)F GZRZBGSFUXNRJK-UHFFFAOYSA-N 0.000 description 1
- AWNGGHPZQDDHRA-UHFFFAOYSA-N Cc([n](C)c1c2)c(C(NC)=O)c1ccc2OC1=C2SC(c3cncnc3)=CC2NC=C1 Chemical compound Cc([n](C)c1c2)c(C(NC)=O)c1ccc2OC1=C2SC(c3cncnc3)=CC2NC=C1 AWNGGHPZQDDHRA-UHFFFAOYSA-N 0.000 description 1
- IWOSEHXSWRCQDI-UHFFFAOYSA-N Cc([n](C)c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(-c1ccncc1)c2 Chemical compound Cc([n](C)c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(-c1ccncc1)c2 IWOSEHXSWRCQDI-UHFFFAOYSA-N 0.000 description 1
- PTGOKSHFOJCAIP-UHFFFAOYSA-N Cc([n](C)c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(-c1ncccc1)c2 Chemical compound Cc([n](C)c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(-c1ncccc1)c2 PTGOKSHFOJCAIP-UHFFFAOYSA-N 0.000 description 1
- YNHOCCULFYKDQK-UHFFFAOYSA-N Cc([n](C)c1c2)c(C(NCCCO)=O)c1ccc2O Chemical compound Cc([n](C)c1c2)c(C(NCCCO)=O)c1ccc2O YNHOCCULFYKDQK-UHFFFAOYSA-N 0.000 description 1
- TVIQWTABSUSMHZ-UHFFFAOYSA-N Cc([o]c1c2)c(C(NCc3ccncc3)=O)c1ccc2Oc1ccnc2c1[s]cc2 Chemical compound Cc([o]c1c2)c(C(NCc3ccncc3)=O)c1ccc2Oc1ccnc2c1[s]cc2 TVIQWTABSUSMHZ-UHFFFAOYSA-N 0.000 description 1
- MNPIYFNULMJMIM-UHFFFAOYSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(-c3ncc[n]3C)cc2ncc1 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(-c3ncc[n]3C)cc2ncc1 MNPIYFNULMJMIM-UHFFFAOYSA-N 0.000 description 1
- ILNRTIUADGNLPW-IYBDPMFKSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(C(N(C[C@H]3O)C[C@@H]3O)=O)cc2ncc1 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1c2[s]c(C(N(C[C@H]3O)C[C@@H]3O)=O)cc2ncc1 ILNRTIUADGNLPW-IYBDPMFKSA-N 0.000 description 1
- OBVDFRNCNVQQPL-UHFFFAOYSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(C1)CC1O)=O)c2 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(C1)CC1O)=O)c2 OBVDFRNCNVQQPL-UHFFFAOYSA-N 0.000 description 1
- XPOXSTQZQZYNNG-OAHLLOKOSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(CC1)C[C@@H]1OC)=O)c2 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(CC1)C[C@@H]1OC)=O)c2 XPOXSTQZQZYNNG-OAHLLOKOSA-N 0.000 description 1
- BWBGNAWDQPVAFL-AWEZNQCLSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](CO)CCC1)=O)c2 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](CO)CCC1)=O)c2 BWBGNAWDQPVAFL-AWEZNQCLSA-N 0.000 description 1
- FLOZCQBCARZKPU-HNNXBMFYSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](COC)CCC1)=O)c2 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](COC)CCC1)=O)c2 FLOZCQBCARZKPU-HNNXBMFYSA-N 0.000 description 1
- IYLANZRWJUEYBV-UHFFFAOYSA-N Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(COCCN1CCCC1)c2 Chemical compound Cc([s]c1c2)c(C(NC)=O)c1ccc2Oc1ccnc2c1[s]c(COCCN1CCCC1)c2 IYLANZRWJUEYBV-UHFFFAOYSA-N 0.000 description 1
- JSNGZHZZZAWMTI-KRWDZBQOSA-N Cc([s]c1c2)c(C(NC3CC3)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](COC)CCC1)=O)c2 Chemical compound Cc([s]c1c2)c(C(NC3CC3)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1[C@H](COC)CCC1)=O)c2 JSNGZHZZZAWMTI-KRWDZBQOSA-N 0.000 description 1
- WEEZQZJWVSOKTD-UHFFFAOYSA-N Cc([s]c1c2)c(C(NCC3CC3)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1CCC1)=O)c2 Chemical compound Cc([s]c1c2)c(C(NCC3CC3)=O)c1ccc2Oc1ccnc2c1[s]c(C(N1CCC1)=O)c2 WEEZQZJWVSOKTD-UHFFFAOYSA-N 0.000 description 1
- KTZLKQDMVFYBJI-OAHLLOKOSA-N Cc([s]c1c2)c(C(OC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(CC1)C[C@@H]1OC)=O)c2 Chemical compound Cc([s]c1c2)c(C(OC)=O)c1ccc2Oc1ccnc2c1[s]c(C(N(CC1)C[C@@H]1OC)=O)c2 KTZLKQDMVFYBJI-OAHLLOKOSA-N 0.000 description 1
- BYOHIXNLDGNVSZ-HZOYBUBWSA-N Cc1c(C(NC)=O)c(ccc(OC2=CCNc3c2[s]c(/C(/NC)=C/C=N)c3)c2)c2[s]1 Chemical compound Cc1c(C(NC)=O)c(ccc(OC2=CCNc3c2[s]c(/C(/NC)=C/C=N)c3)c2)c2[s]1 BYOHIXNLDGNVSZ-HZOYBUBWSA-N 0.000 description 1
- AJFCFHUIFUPHBV-UHFFFAOYSA-N Cc1c(C(NC)=O)c(ccc(Oc2ccnc3c2[s]c(C(N2CC(CN)CC2)=O)c3)c2)c2[n]1C Chemical compound Cc1c(C(NC)=O)c(ccc(Oc2ccnc3c2[s]c(C(N2CC(CN)CC2)=O)c3)c2)c2[n]1C AJFCFHUIFUPHBV-UHFFFAOYSA-N 0.000 description 1
- HUWCCPSRSXXDPO-UHFFFAOYSA-N Cc1c(C(NCCc2c[nH]c3cc(F)ccc23)=O)c(ccc(Oc2ccnc3c2[s]cc3)c2)c2[o]1 Chemical compound Cc1c(C(NCCc2c[nH]c3cc(F)ccc23)=O)c(ccc(Oc2ccnc3c2[s]cc3)c2)c2[o]1 HUWCCPSRSXXDPO-UHFFFAOYSA-N 0.000 description 1
- SPIQAGPALJODCN-UHFFFAOYSA-N Cc1cc(nccc2Cl)c2[s]1 Chemical compound Cc1cc(nccc2Cl)c2[s]1 SPIQAGPALJODCN-UHFFFAOYSA-N 0.000 description 1
- OGXMJWAGXCEGHL-UHFFFAOYSA-N Cc1cc2nccc(Oc(cc3)cc4c3c(C(NCCN3CCOCC3)=O)c(C)[s]4)c2[s]1 Chemical compound Cc1cc2nccc(Oc(cc3)cc4c3c(C(NCCN3CCOCC3)=O)c(C)[s]4)c2[s]1 OGXMJWAGXCEGHL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38911002P | 2002-06-14 | 2002-06-14 | |
| US60/389,110 | 2002-06-14 | ||
| PCT/IB2003/002393 WO2003106462A1 (en) | 2002-06-14 | 2003-06-04 | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067019988A Division KR100714545B1 (ko) | 2002-06-14 | 2003-06-04 | 치료제로 유용한 티에노피리딘의 벤조융합된 헤테로아릴아마이드 유도체를 포함하는 약학 조성물 및 그의 사용방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20050008821A KR20050008821A (ko) | 2005-01-21 |
| KR100671632B1 true KR100671632B1 (ko) | 2007-02-28 |
Family
ID=29736588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067019988A Expired - Fee Related KR100714545B1 (ko) | 2002-06-14 | 2003-06-04 | 치료제로 유용한 티에노피리딘의 벤조융합된 헤테로아릴아마이드 유도체를 포함하는 약학 조성물 및 그의 사용방법 |
| KR1020047020286A Expired - Fee Related KR100671632B1 (ko) | 2002-06-14 | 2003-06-04 | 치료제로 유용한 티에노피리딘의 벤조융합된 헤테로아릴 아마이드 유도체 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067019988A Expired - Fee Related KR100714545B1 (ko) | 2002-06-14 | 2003-06-04 | 치료제로 유용한 티에노피리딘의 벤조융합된 헤테로아릴아마이드 유도체를 포함하는 약학 조성물 및 그의 사용방법 |
Country Status (36)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1506962B1 (en) * | 2000-10-20 | 2008-07-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic heterocycles |
| ATE374768T1 (de) * | 2002-10-03 | 2007-10-15 | Hoffmann La Roche | Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren |
| JPWO2004080462A1 (ja) * | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | ｃ−Ｋｉｔキナーゼ阻害剤 |
| US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
| JP4303726B2 (ja) * | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| EP1711495A2 (en) * | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
| EP2364699A1 (en) | 2004-09-13 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Joint use of sulfonamide based compound with angiogenesis inhibitor |
| US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| US8969379B2 (en) * | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| WO2006043172A1 (en) * | 2004-10-19 | 2006-04-27 | Pfizer Inc. | Pharmaceutical compositions and methods for sub-tenon delivery |
| WO2006117666A2 (en) * | 2005-04-29 | 2006-11-09 | Pfizer Inc. | Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| KR100990590B1 (ko) * | 2005-09-01 | 2010-10-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 붕해성이 개선된 의약 조성물의 제조 방법 |
| AR055625A1 (es) * | 2005-09-02 | 2007-08-29 | Pfizer | Procedimientos mejorados para preparar derivados de tienopiridinas heteroaril amida benzocondensados |
| US20090053236A1 (en) * | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| US8003662B2 (en) | 2006-01-30 | 2011-08-23 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds and methods of use |
| KR20080102181A (ko) * | 2006-02-15 | 2008-11-24 | 알러간, 인코포레이티드 | 스핑고신-1-포스페이트 (에스1피) 수용체 길항제 생물학적 활성을 갖는 아릴 또는 헤테로아릴기를 포함하는 인돌-3-카르보실산 아미드, 에스테르, 티오아미드 및 티올 에스테르 화합물 |
| GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| CA2652442C (en) * | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| EP2065372B1 (en) * | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US8962655B2 (en) * | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| WO2009026720A1 (en) * | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| AU2008293038B2 (en) * | 2007-08-29 | 2013-08-29 | Mirati Therapeutics, Inc. | Inhibitors of protein tyrosine kinase activity |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| BRPI0906576A2 (pt) * | 2008-01-29 | 2015-07-07 | Eisai R&D Man Co Ltd | Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer |
| ES2357682T3 (es) * | 2008-03-25 | 2011-04-28 | Affectis Pharmaceuticals Ag | Antagonistas de p2x7r novedosos y su utilización. |
| US8815892B2 (en) | 2008-03-25 | 2014-08-26 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| AU2010289353B2 (en) * | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
| ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
| AU2011280969A1 (en) | 2010-07-23 | 2013-02-07 | Trustees Of Boston University | Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| MX2013009931A (es) | 2011-04-18 | 2013-10-01 | Eisai R&D Man Co Ltd | Agentes terapeuticos contra tumores. |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN113683564A (zh) | 2014-08-28 | 2021-11-23 | 卫材R&D管理有限公司 | 高纯度喹啉衍生物及其生产方法 |
| CN104628686A (zh) * | 2015-01-27 | 2015-05-20 | 南通恒盛精细化工有限公司 | 一种带酰胺侧链的苯并呋喃制备工艺 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| CA2978226C (en) | 2015-03-04 | 2025-02-18 | Eisai R&D Management Co., Ltd. | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER |
| CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
| RU2718048C2 (ru) | 2015-08-20 | 2020-03-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
| WO2018147275A1 (ja) | 2017-02-08 | 2018-08-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| US20220056043A1 (en) * | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
| CN114269753B (zh) * | 2019-09-29 | 2024-03-05 | 四川科伦博泰生物医药股份有限公司 | 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559616A (en) * | 1984-10-03 | 1985-12-17 | Quadri Corporation | Fast, non-volatile semiconductor/bubble memory with temperature-compensated magnetic bias field |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| FI941572L (fi) * | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| EP1997894B1 (en) * | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5736534A (en) | 1994-02-23 | 1998-04-07 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
| JPH10509708A (ja) | 1994-11-10 | 1998-09-22 | コア セラピューティクス，インコーポレイティド | プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物 |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| MX9708026A (es) * | 1995-04-20 | 1997-11-29 | Pfizer | Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos. |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| ATE247469T1 (de) | 1995-06-07 | 2003-09-15 | Pfizer | Heterocyclische kondensierte pyrimidin-derivate |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| CA2259222A1 (en) * | 1996-06-27 | 1997-12-31 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| IL127567A0 (en) | 1996-07-18 | 1999-10-28 | Pfizer | Phosphinate based inhibitors of matrix metalloproteases |
| JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク． | アリールスルホニルアミノヒドロキサム酸誘導体 |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| IL129825A0 (en) | 1996-11-27 | 2000-02-29 | Pfizer | Fused bicyclic pyrimidine derivatives |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
| EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| CA2280151C (en) | 1997-02-11 | 2005-12-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
| US5835420A (en) | 1997-06-27 | 1998-11-10 | Aplus Flash Technology, Inc. | Node-precise voltage regulation for a MOS memory system |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| US6061742A (en) * | 1997-10-10 | 2000-05-09 | Nortel Networks Corporation | Computer network adaptor |
| CN1158269C (zh) | 1997-10-27 | 2004-07-21 | 阿古龙制药公司 | 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物 |
| BR9814018A (pt) * | 1997-11-11 | 2000-09-26 | Pfizer Prod Inc | Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| US6269027B1 (en) * | 1998-04-14 | 2001-07-31 | Honeywell, Inc. | Non-volatile storage latch |
| IL139934A (en) | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
| EP1140194A2 (en) | 1998-12-23 | 2001-10-10 | G.D. SEARLE & CO. | Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia |
| DE10015193A1 (de) * | 2000-03-27 | 2001-10-25 | Infineon Technologies Ag | Hochintegrierte System-on-Chip-Systeme mit nichtflüchtigen Speichereinheiten |
| WO2001094353A1 (en) * | 2000-06-06 | 2001-12-13 | Pfizer Products Inc. | Thiophene derivatives useful as anticancer agents |
| AU2002345792A1 (en) * | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| CA2478050A1 (en) | 2002-03-01 | 2003-09-12 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
-
2003
- 2003-04-06 UA UA20041210250A patent/UA77303C2/uk unknown
- 2003-06-04 BR BR0311806-1A patent/BR0311806A/pt not_active IP Right Cessation
- 2003-06-04 KR KR1020067019988A patent/KR100714545B1/ko not_active Expired - Fee Related
- 2003-06-04 ES ES03727888T patent/ES2290460T3/es not_active Expired - Lifetime
- 2003-06-04 JP JP2004513293A patent/JP2005534669A/ja not_active Withdrawn
- 2003-06-04 HR HR20041173A patent/HRP20041173A2/hr not_active Application Discontinuation
- 2003-06-04 AP AP2004003184A patent/AP2004003184A0/xx unknown
- 2003-06-04 OA OA1200400325A patent/OA12865A/en unknown
- 2003-06-04 RS YU107504A patent/RS107504A/sr unknown
- 2003-06-04 MX MXPA04011637A patent/MXPA04011637A/es unknown
- 2003-06-04 GE GEAP8535A patent/GEP20074033B/en unknown
- 2003-06-04 PL PL03374542A patent/PL374542A1/xx not_active Application Discontinuation
- 2003-06-04 CN CNA038181096A patent/CN1671714A/zh active Pending
- 2003-06-04 CA CA002489466A patent/CA2489466A1/en not_active Abandoned
- 2003-06-04 KR KR1020047020286A patent/KR100671632B1/ko not_active Expired - Fee Related
- 2003-06-04 EA EA200500018A patent/EA008255B1/ru unknown
- 2003-06-04 AU AU2003233134A patent/AU2003233134A1/en not_active Abandoned
- 2003-06-04 EP EP03727888A patent/EP1515975B1/en not_active Expired - Lifetime
- 2003-06-04 WO PCT/IB2003/002393 patent/WO2003106462A1/en not_active Ceased
- 2003-06-04 AT AT03727888T patent/ATE373665T1/de not_active IP Right Cessation
- 2003-06-04 DE DE60316440T patent/DE60316440T2/de not_active Expired - Fee Related
- 2003-06-04 NZ NZ537140A patent/NZ537140A/en unknown
- 2003-06-11 US US10/460,010 patent/US6869962B2/en not_active Expired - Fee Related
- 2003-06-11 PE PE2003000579A patent/PE20050123A1/es not_active Application Discontinuation
- 2003-06-12 GT GT200300129A patent/GT200300129A/es unknown
- 2003-06-12 PA PA20038575401A patent/PA8575401A1/es unknown
- 2003-06-13 AR ARP030102121A patent/AR039673A1/es not_active Application Discontinuation
- 2003-06-13 HN HN2003000182A patent/HN2003000182A/es unknown
- 2003-06-13 TW TW092116098A patent/TW200404070A/zh unknown
-
2004
- 2004-03-09 US US10/796,226 patent/US7045528B2/en not_active Expired - Fee Related
- 2004-11-24 NO NO20045103A patent/NO20045103L/no not_active Application Discontinuation
- 2004-11-25 IS IS7552A patent/IS7552A/is unknown
- 2004-12-06 ZA ZA200409862A patent/ZA200409862B/xx unknown
- 2004-12-06 IL IL16559104A patent/IL165591A0/xx unknown
- 2004-12-08 MA MA27986A patent/MA27596A1/fr unknown
- 2004-12-09 EC EC2004005483A patent/ECSP045483A/es unknown
- 2004-12-09 CO CO04123221A patent/CO5631447A2/es not_active Application Discontinuation
- 2004-12-13 TN TNP2004000246A patent/TNSN04246A1/fr unknown
-
2005
- 2005-10-21 US US11/256,477 patent/US20060079548A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100671632B1 (ko) | 치료제로 유용한 티에노피리딘의 벤조융합된 헤테로아릴 아마이드 유도체 | |
| CN105777776B (zh) | 蛋白酪氨酸激酶活性的抑制剂 | |
| CN101133056B (zh) | 抗肿瘤化合物 | |
| US6770641B2 (en) | Fused heteroaryl derivatives | |
| TWI553005B (zh) | 經取代之酞－１（２ｈ）－酮衍生物 | |
| CA2941771C (en) | Heterocyclic compounds, process for preparation of the same and use thereof | |
| JP2005527511A (ja) | 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法 | |
| JP2008266349A (ja) | ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途 | |
| CA2502614A1 (en) | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | |
| CN101796055A (zh) | Vegf受体和hgf受体信号的抑制剂 | |
| US20080070913A1 (en) | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | |
| JP2007504121A (ja) | 新たな抗血管形成剤として有用なナフタレン・カルボキサミド及びその誘導体 | |
| CN101677547A (zh) | 作为ikk2抑制剂的吲哚甲酰胺 | |
| JP4160295B2 (ja) | ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途 | |
| KR20120078703A (ko) | 융합 헤테로시클릭 고리 유도체 및 이의 용도 | |
| HK1077826A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| J201 | Request for trial against refusal decision | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
St.27 status event code: A-3-4-F10-F13-rex-PB0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20100113 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20100113 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |